|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
|
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash | ||||||||
| Prepaid expenses | ||||||||
| Deferred offering costs | ||||||||
| Marketable securities held in Trust Account-current | ||||||||
| Total current assets | ||||||||
| Marketable securities held in Trust Account | ||||||||
| Total current assets | ||||||||
| TOTAL ASSETS | ||||||||
| Liabilities, Ordinary Shares Subject to Possible Redemption and Shareholders’ Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued expenses | ||||||||
| Due to a related party | ||||||||
| Promissory note - a related party | ||||||||
| Total current liabilities | ||||||||
| Total Liabilities | ||||||||
| Ordinary shares subject to possible redemption, 5,750,000 shares subject to possible redemption at June 30, 2026 and December 31, 2025 | ||||||||
| Shareholders’ (Deficit) Equity: | ||||||||
| Ordinary shares, $0.0001 par value, 500,000,000 shares authorized, 1,794,000 shares issued and outstanding (excluding 5,750,000 shares subject to redemption) at June 30, 2026 and December 31, 2025 | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ||||||||
| Total Shareholders’ (Deficit) Equity | ||||||||
| TOTAL LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS’ (DEFICIT) EQUITY |
Loading...
